OncoMatch/Clinical Trials/NCT07238712
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
Is NCT07238712 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Ruxolitinib and Abatacept (Orencia) for acute myeloid leukemia (aml).
Treatment: Ruxolitinib · Abatacept (Orencia) — Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Biomarker criteria
Required: TP53 mutation
Demographics
Prior therapy
Must have received: allogeneic stem cell transplant — second or subsequent allogeneic HCT after relapse of a myeloid malignancy
Second or subsequent allogeneic HCT after relapse of a myeloid malignancy
Must have received: induction therapy — AML with >5% of clonal blasts in bone marrow despite adequate previous induction therapy
Acute myeloid leukemia: >5% of clonal blasts in bone marrow despite adequate previous induction therapy or allogeneic stem cell transplantation
Must have received: — MDS with >5% of blasts despite previous therapy
Myelodysplastic Syndrome: >5% of blasts despite previous therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07238712 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received allogeneic stem cell transplant and induction therapy.
Does this trial require TP53?
Yes, TP53 mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify